3
Announcements
Trials
Browse
Landscape
Sponsor
Conditions
Melanoma
8
Glioma
4
Multiple Myeloma
3
Thyroid Neoplasms
2
Neoplasms
2
Neoplasm Metastasis
2
Lymphoma
2
Lung Neoplasms
2
Hematologic Neoplasms
2
Glioblastoma
2
Colorectal Neoplasms
2
Astrocytoma
2
Uterine Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Thyroid Carcinoma, Anaplastic
1
Stomach Neoplasms
1
Spinocerebellar Degenerations
1
Sarcoma
1
Refractory Differentiated Thyroid Gland Carcinoma
1
Rectal Neoplasms
1
Prostatic Neoplasms
1
Pancreatic Neoplasms
1
Ovarian Neoplasms
1
Oligodendroglioma
1
Neurofibromatosis 1
1
Neurofibroma, Plexiform
1
Neurocytoma
1
Neuroblastoma
1
Metastatic Radioactive Iodine Refractory Thyroid Cancer Patients With RAS or BRAF Mutation
1
Interventions
pembrolizumab
8
cemiplimab
5
Nivolumab
4
Ipilimumab
4
Blood Specimen Collection
3
lifileucel
2
avelumab
2
aldesleukin
2
Niacinamide
2
Cyclophosphamide
2
toripalimab
1
tislelizumab
1
oxycodone-acetaminophen
1
lenvatinib
1
fludarabine
1
epacadostat
1
encorafenib
1
durvalumab
1
dostarlimab
1
brodalumab
1
binimetinib
1
atezolizumab
1
Vitamin A
1
Surgical Procedures, Operative
1
Sunscreening Agents
1
Standard of Care
1
Specimen Handling
1
Resistance Training
1
Radiotherapy
1
Niacin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
0 trials
Recent
Start date
Enrollment
Skin Neoplasms
×
dabrafenib
×
90 days
×
Clear all
No trials found.